Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Stemline Therapeutic (STML)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 433,130
  • Shares Outstanding, K 31,801
  • Annual Sales, $ 900 K
  • Annual Income, $ -67,830 K
  • 60-Month Beta 1.12
  • Price/Sales 388.79
  • Price/Cash Flow N/A
  • Price/Book 6.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.53
  • Number of Estimates 2
  • High Estimate -0.50
  • Low Estimate -0.56
  • Prior Year -0.69
  • Growth Rate Est. (year over year) +23.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.57 +22.04%
on 02/28/19
13.81 -6.59%
on 03/14/19
+1.41 (+12.27%)
since 02/15/19
3-Month
7.82 +64.96%
on 12/21/18
13.81 -6.59%
on 03/14/19
+2.54 (+24.52%)
since 12/18/18
52-Week
7.82 +64.96%
on 12/21/18
20.55 -37.23%
on 06/05/18
-1.15 (-8.19%)
since 03/16/18

Most Recent Stories

More News
Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that Ivan Bergstein,...

STML : 12.90 (-5.29%)
Stemline Therapeutics: 4Q Earnings Snapshot

NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Friday reported a loss of $26.6 million in its fourth quarter.

STML : 12.90 (-5.29%)
Stemline Therapeutics Reports Fourth Quarter 2018 Financial Results

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today financial results...

STML : 12.90 (-5.29%)
Uptrend Call Working As Stemline Therape Stock Rises 29.3% (STML)

SmarTrend identified an Uptrend for Stemline Therape (NASDAQ:STML) on January 18th, 2019 at $10.45. In approximately 2 months, Stemline Therape has returned 29.34% as of today's recent price of $13.51....

STML : 12.90 (-5.29%)
Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that it has exclusively...

STML : 12.90 (-5.29%)
Stemline Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein,...

STML : 12.90 (-5.29%)
Shares of Stemline Therape Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (STML , ALNY , SRPT , ESPR , PTCT )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

SRPT : 126.82 (-1.20%)
STML : 12.90 (-5.29%)
ALNY : 90.24 (-1.30%)
Watch for Stemline Therape to Potentially Pullback After Gaining 4.29% Yesterday

Stemline Therape (NASDAQ:STML) traded in a range yesterday that spanned from a low of $11.42 to a high of $11.90. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high...

STML : 12.90 (-5.29%)
Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Marriott International (NASDAQ:MAR),...

STML : 12.90 (-5.29%)
CVGW : 84.94 (-1.19%)
MAR : 124.96 (+2.16%)
KNSL : 69.20 (-0.14%)
FLDM : 13.81 (+1.17%)
GSBD : 20.79 (+0.92%)
Stemline Therapeutics Closes $92 Million Public Offering of Common Stock

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced...

JPM : 107.19 (+0.60%)
STML : 12.90 (-5.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade STML with:

Business Summary

Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric...

See More

Key Turning Points

2nd Resistance Point 14.11
1st Resistance Point 13.50
Last Price 12.90
1st Support Level 12.22
2nd Support Level 11.55

See More

52-Week High 20.55
Fibonacci 61.8% 15.69
Fibonacci 50% 14.18
Last Price 12.90
Fibonacci 38.2% 12.68
52-Week Low 7.82

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar